New hope for myeloma patients: iberdomide trial targets suboptimal transplant responses

NCT ID NCT05354557

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug iberdomide can safely improve outcomes for people with multiple myeloma who had a less-than-ideal response after a stem cell transplant and previous maintenance therapy. Sixteen participants will take iberdomide and be monitored for disease progression and side effects. The goal is to see if more patients achieve a complete response within six months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Memorial Sloan Kettering Basking Ridge (Consent and Followup)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Consent and Follow up)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All protocol activities)

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth (Consent and Follow-Up only)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Consent and Followup)

Rockville Centre, New York, 11553, United States
Memorial Sloan Kettering Suffolk-Commack (Consent and Follow up)

Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (Consent and Follow Up)

Harrison, New York, 10604, United States
Weill Cornell Medical College (Data Collection Only)

New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.